Revenue grew 6% at CER in H1 2026, led by 15% oncology growth and strong rare disease performance, while BioPharmaceuticals declined due to LOE impacts. Pipeline momentum continued with six positive Phase III readouts and first approvals for multiple NMEs.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.